Under a tenth of people that would benefit from obesity jabs like Wegovy have access to them, states the World Health Organization as it releases its first recommendations on the medications.
Considering over a billion individuals worldwide now obese, it is urging broader and more equitable availability to GLP-1 medication.
Per forecasts, over two billion could be living with obesity by 2030 unless action is taken.
"Our new guidelines acknowledges that obesity is a long-term condition that can be managed with holistic and ongoing support," stated WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and supply-chain constraints are key barriers to widespread availability to the treatments that can help people shift substantial weight, explains the agency.
GLP-1 Therapy Scarcity
Even in the present most optimistic case, the supply of such drugs might only reach about 100 million people – fewer than 10% of the global need, according to the health organization.
The advice urges governments and firms to increase access, by strategies like licensing agreements.
The intellectual property rights on a key compound – the main ingredient of the drug Wegovy – is scheduled to end in a number of nations in 2026.
The Way Weight-Loss Jabs Function
GLP-1 drugs mimick a natural hormone to slow digestion, suppress the appetite and boost the sense of being full so individuals consume fewer calories.
Patients usually see weight reduction in the initial weeks of commencing the once-weekly jabs.
Studies suggests patients may put most of the weight back on within a year of stopping the drug, because their typical hunger return.
To be carrying excess weight raises your likelihood for experiencing diseases, including type 2 diabetes, heart disease, stroke, and specific malignancies.
Obesity impacts people in all nations and was associated with millions of deaths worldwide in 2024, according to the health agency.
